Dr. Zachary Hunter recently spoke at an Atlantic Support Group Zoom Meeting. Click on the link below to view his presentation entitled “What is New in Waldenstrom’s Macroglobulinemia Research?” His talk is followed by a question and answer session.
Meletios A. Dimopoulos, MD, discusses safety results from the randomized phase 3 ASPEN trial of zanubrutinib (Brukinsa) in patients with Waldenström macroglobulinemia.
-June 14/20 Published here: onclive.com-
Meletios A. Dimopoulos, MD, professor and chairman of the Department of Clinical Therapeutics at… Continue reading
In the first head-to-head comparison of Bruton tyrosine kinase (BTK) inhibitors, zanubrutinib demonstrated statistically significant and clinically meaningful advantages in safety and tolerability in patients with Waldenström macroglobulinemia (WM) compared with ibrutinib. Although zanubrutinib yielded a numerically higher response rate… Continue reading
In this video, an international panel of experts sat down with Oncology Learning Network to discuss the 3 Bruton’s tyrosine kinase (BTK) inhibitors active in the treatment of Waldenström macroglobulinemia (WM): ibrutinib, acalabrutinib, and zanubrutinib.
This discussion is moderated by… Continue reading
Dr. Jorge Castillo – Associate Professor of Medicine, Harvard University – presenting “Treatment around the corner for Waldenstroms Macroglobulinemia” at the 2019 WMFC Educational Forum Toronto – April 2019
Dr. Christine Chen from the Princess Margaret Cancer Centre presenting on ” Navigating Treatment Options for Waldenstrom’s Macroglobulinemia in Canada” at the 2019 WMFC Educational Forum Toronto – April 2019
Dr. Ruben Carrasco from the Department of Pathology, BWH and Department of Oncologic Pathology, DFCI presenting: Engineering a mouse model of Lymphoplasmacytic Lymphoma/Waldenstroms Macroglobulinemia (LPL/WM) at the 2019 WMFC Educational Forum Toronto – April 2019
Dr. Stephen Ansell, Professor of Medicine, Mayo Clinic
Presenting: Immunotherapy – Getting the immune system to target WM cells
Dr. Steven Treon – Bing Center for Waldenstroms Macroglobulinemia, Dana Farber Cancer Institute, Harvard Medical School
Presenting: Waldenstroms Macroglobulinemia: Genomic Based Treatment Advances